NCT01604889 2026-04-21
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Incyte Corporation
Phase 1/2 Terminated
Clinical Trials
9 trialsNCT04410874 2024-03-07
MUSIC-01
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 1/2 Terminated
NCT00003552 2024-03-04
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT03684785 2022-04-07
Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
Exicure, Inc.
Phase 1/2 Terminated
NCT02521870 2021-08-03
SYNERGY-001
Dynavax Technologies Corporation
Phase 1/2 Terminated
NCT03391050 2019-07-31
A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma
Aprea Therapeutics
Phase 1/2 Terminated
NCT01236573 2015-11-26
Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00278018 2015-04-21
Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors
Hadassah Medical Organization
Phase 1/2 Terminated
NCT01369888 2015-01-27
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated